Compositions and methods for treating, including preventing, parvovirus infections and related diseases

Abstract

Some embodiments of the invention include inventive polypeptides (e.g., mutant VP2 proteins) and virus-like particles made from the inventive polypeptides. Other embodiments of the invention include compositions for treating (e.g., preventing) parvovirus (e.g., erythrovirus or parvovirus B19) infection and other diseases. Further embodiments include methods for administering compositions to an animal. Other embodiments include treating (e.g., preventing) parvovirus (e.g., erythrovirus or parvovirus B19) infection and other diseases. Still other embodiments include nucleic acid sequences that encode the inventive polypeptides. Additional embodiments of the invention are also discussed.

What is claimed is: 
     
         1 .- 87 . (canceled) 
     
     
         88 . A method for treating an animal for a parvovirus infection, an erythrovirus infection, or a parvovirus B19 infection, comprising one or more administrations of one or more compositions comprising an mVLP comprising a polypeptide,
 wherein
 the treating is (i) ameliorating or relieving symptoms of the parvovirus infection, the erythrovirus infection, or the parvovirus B19 infection, (ii) inhibiting the development or progression of the parvovirus infection, the erythrovirus infection, or the parvovirus B19 infection, (iii) reducing the severity of the parvovirus infection, the erythrovirus infection, or the parvovirus B19 infection, (iv) causing a regression of the parvovirus infection, the erythrovirus infection, or the parvovirus B19 infection, or (v) a combination thereof 
 the compositions may be the same or different if there is more than one administration, 
 the polypeptide comprises a VP2 polypeptide with at least one amino acid modification relative to a wild type VP2, 
 the wild type VP2 has the amino acid sequence of SEQ ID NO: 1, 
 the at least one amino acid modification (1) comprises (a) Y401F and (b) Q399N or Q404T or (2) is Y401F, and 
 the polypeptide is not construct J. 
   
     
     
         89 . The method of  claim 88 , wherein at least one of the one or more compositions does not comprise an adjuvant. 
     
     
         90 . The method of  claim 88 , wherein at least one of the one or more compositions further comprises a carrier or an adjuvant. 
     
     
         91 . The method of  claim 88 , wherein at least one of the one or more compositions further comprises squalene, IL-2, RIBI adjuvant system, QS21, GM-CSF, alum hydro gel, monophosphoryl lipid A, trehalose dimycolate, Toll-like receptor ligands, Toll-like receptor agonists, CpG oligodeoxynucleotides, cell wall skeleton, MF59, or combinations thereof. 
     
     
         92 . The method of  claim 88 , wherein at least one of the one or more the compositions comprises a pharmaceutical composition or a vaccine. 
     
     
         93 . The method of  claim 88 , wherein at least one of the one or more administrations comprises parenteral administration, a mucosal administration, intravenous administration, subcutaneous administration, topical administration, intradermal administration, oral administration, sublingual administration, intranasal administration, or intramuscular administration. 
     
     
         94 . The method of  claim 88 , wherein if there is more than one administration at least one composition used for at least one administration is different from the composition of at least one other administration. 
     
     
         95 . The method of  claim 88 , wherein the mVLP of at least one of the one or more compositions is administered to the animal in an amount of from about 0.01 mg of mVLP/kg animal body weight to about 15 mg of mVLP/kg animal body weight. 
     
     
         96 . The method of  claim 88 , wherein the animal is a human or a primate. 
     
     
         97 . The method of  claim 88 , wherein the animal is in need of the treating. 
     
     
         98 . The method of  claim 88 , wherein the method is for treating an erythrovirus infection. 
     
     
         99 . The method of  claim 88 , wherein the method is for treating a parvovirus B19 infection. 
     
     
         100 . The method of  claim 88 , wherein the method induces an immune response. 
     
     
         101 . The method of  claim 88 , wherein the at least one amino acid modification comprises (a) Y401F and (b) Q399N or Q404T and further comprises an insertion, a deletion, or a substitution. 
     
     
         102 . The method of  claim 88 , wherein the polypeptide sequence has at least about 90% identity to SEQ ID NO: 1. 
     
     
         103 . The method of  claim 88 , wherein the polypeptide sequence has at least about 95% identity to SEQ ID NO: 1. 
     
     
         104 . The method of  claim 88 , wherein the polypeptide is Construct A. 
     
     
         105 . The method of  claim 88 , wherein the polypeptide is Construct F. 
     
     
         106 . The method of  claim 88 , wherein the at least one amino acid modification comprises (a) Y401F and (b) Q399N or Q404T. 
     
     
         107 . The method of  claim 88 , wherein the mVLP has reduced binding to P antigen compared to wtVLP, the mVLP has no detectable binding to P antigen, the mVLP has reduced hemagglutination of red blood cells compared to wtVLP, or the mVLP has no detectable hemagglutination. 
     
     
         108 . The method of  claim 88 , wherein the mVLP has one or more neutralizing epitopes. 
     
     
         109 . The method of  claim 88 , wherein the mVLP induces the production of antibodies in an animal, where the antibodies produced are capable of reducing or inhibiting hemagglutination by wtVLP. 
     
     
         110 . The method of  claim 88 , wherein the treating is ameliorating or relieving symptoms of the erythrovirus infection or the parvovirus B19 infection. 
     
     
         111 . The method of  claim 88 , wherein the treating is inhibiting the development or progression of the erythrovirus infection or the parvovirus B19 infection. 
     
     
         112 . The method of  claim 88 , wherein the treating is reducing the severity of the erythrovirus infection or the parvovirus B19 infection. 
     
     
         113 . The method of  claim 88 , wherein the treating is causing a regression of the erythrovirus infection or the parvovirus B19 infection.